top of page

By:

Quaid Najmi

4 January 2025 at 3:26:24 pm

Congress’ solo path for ‘ideological survival’

Mumbai: The Congress party’s decision to contest the forthcoming BrihanMumbai Municipal Corporation (BMC) elections independently is being viewed as an attempt to reclaim its ideological space among the public and restore credibility within its cadre, senior leaders indicated. The announcement - made by AICC General Secretary Ramesh Chennithala alongside state president Harshwardhan Sapkal and Mumbai Congress chief Varsha Gaikwad - did not trigger a backlash from the Maharashtra Vikas Aghadi...

Congress’ solo path for ‘ideological survival’

Mumbai: The Congress party’s decision to contest the forthcoming BrihanMumbai Municipal Corporation (BMC) elections independently is being viewed as an attempt to reclaim its ideological space among the public and restore credibility within its cadre, senior leaders indicated. The announcement - made by AICC General Secretary Ramesh Chennithala alongside state president Harshwardhan Sapkal and Mumbai Congress chief Varsha Gaikwad - did not trigger a backlash from the Maharashtra Vikas Aghadi (MVA) partners, the Nationalist Congress Party (SP) and Shiv Sena (UBT). According to Congress insiders, the move is the outcome of more than a year of intense internal consultations following the party’ dismal performance in the 2024 Assembly elections, belying huge expectations. A broad consensus reportedly emerged that the party should chart a “lone-wolf” course to safeguard the core ideals of Congress, turning140-years-old, next month. State and Mumbai-level Congress leaders, speaking off the record, said that although the party gained momentum in the 2019 Assembly and 2024 Lok Sabha elections, it was frequently constrained by alliance compulsions. Several MVA partners, they claimed, remained unyielding on larger ideological and political issues. “The Congress had to compromise repeatedly and soften its position, but endured it as part of ‘alliance dharma’. Others did not reciprocate in the same spirit. They made unilateral announcements and declared candidates or policies without consensus,” a senior state leader remarked. Avoid liabilities He added that some alliance-backed candidates later proved to be liabilities. Many either lost narrowly or, even after winning with the support of Congress workers, defected to Mahayuti constituents - the Bharatiya Janata Party, Shiv Sena, or the Nationalist Congress Party. “More than five dozen such desertions have taken place so far, which is unethical, backstabbing the voters and a waste of all our efforts,” he rued. A Mumbai office-bearer elaborated that in certain constituencies, Congress workers effectively propelled weak allied candidates through the campaign. “Our assessment is that post-split, some partners have alienated their grassroots base, especially in the mofussil regions. They increasingly rely on Congress workers. This is causing disillusionment among our cadre, who see deserving leaders being sidelined and organisational growth stagnating,” he said. Chennithala’s declaration on Saturday was unambiguous: “We will contest all 227 seats independently in the BMC polls. This is the demand of our leaders and workers - to go alone in the civic elections.” Gaikwad added that the Congress is a “cultured and respectable party” that cannot ally with just anyone—a subtle reference to the Maharashtra Navnirman Sena (MNS), which had earlier targeted North Indians and other communities and is now bidding for an electoral arrangement with the SS(UBT). Both state and city leaders reiterated that barring the BMC elections - where the Congress will take the ‘ekla chalo’ route - the MVA alliance remains intact. This is despite the sharp criticism recently levelled at the Congress by senior SS(UBT) leader Ambadas Danve following the Bihar results. “We are confident that secular-minded voters will support the Congress' fight against the BJP-RSS in local body elections. We welcome backing from like-minded parties and hope to finalize understandings with some soon,” a state functionary hinted. Meanwhile, Chennithala’s firm stance has triggered speculation in political circles about whether the Congress’ informal ‘black-sheep' policy vis-a-vis certain parties will extend beyond the BMC polls.

Forensic Battle Against Counterfeit Medicines

In India, counterfeit medicines have quietly become a serious threat, even reaching legitimate shops and hospitals.

ree

India is now increasingly threatened by the growing menace of counterfeit medicines. Counterfeit medicines are fake drugs that look just like the real ones but might not work—or worse, they could harm health. Fake medicines often contain no real ingredients, wrong substances, or harmful chemicals, yet are packaged with labels, logos and seals to look authentic. In India, where medicines are used by millions every day, counterfeit drugs have quietly become a serious threat, even reaching trusted shops and hospitals. These illicit drugs find their way into legitimate supply chains. As counterfeiters grow more sophisticated, spotting and stopping these drugs is increasingly critical.


Counterfeiters target multiple parts of a drug’s presentation. They even exploit the names of reputed pharmaceutical companies to circulate fake medicines in the market, deceiving both regulators and consumers. Counterfeit tablets or capsules often mimic the colour, shape, and size of real drugs but may lack active pharmaceutical ingredients (APIs) or contain harmful substitutes. They differ in texture, weight, and dissolution. Common signs include incorrect fonts, misspellings, poor logos, fake QR codes or holograms that don't link to verification databases, and low-quality packaging. Batch numbers and expiry dates are often printed with non-standard inks, and tamper-evident seals are typically forged, lacking proper pressure sensitivity or adhesive bonding of the genuine products. Counterfeiters use fake licences and illegal manufacturers to dodge regulation.


India is tackling counterfeit drugs with a multi-layered strategy combining forensic science and regulation. Key steps include QR code-based serialisation for full drug traceability and upgrading state and central forensic labs into specialised pharma forensics units. These labs use tools such as Raman spectroscopy, infrared analysis, and AI databases. Experts use visual and digital autopsies to examine packaging and contents, while digital forensics from phones and computers uncovers networks. Fingerprint analysis links suspects to crime scenes, and psychological profiling aids in understanding perpetrators. This integrated approach helps to detect, trace, and dismantle fake drug operations to safeguard public health.


The Parliamentary Standing Committee's fifth report (2024–25) flags widespread spurious drugs and a misleadingly low 5.9% conviction rate. Of 2.3 lakh samples tested (2015–2019), 593 were spurious and 9,266 substandard, yet only 35 convictions occurred. In April 2025, 196 drug samples were declared ‘Not of Standard Quality (NSQ)—60’ by central labs and 136 by state labs. Similar concerns were raised in March 2025 and December 2024, when 135 NSQ drugs were flagged.


Key counterfeit medicine hubs in India include Delhi-NCR, Baddi, Kolkata, Patna, Mumbai, and parts of UP and Hyderabad. These areas are exploited for their pharma activity, weak oversight, and transport access, aiding fake drug production and distribution.


There is currently no centralised national database to track counterfeit medicine cases, which allows repeat offenders to secure bail relatively quickly after serving only a short period in police or judicial custody. Although violators are subjected to provisions under the Drug and Cosmetics Act, enforcement remains challenging.


In November 2024, the Supreme Court issued a notice based on a petition filed by the Indian Pharmaceutical Alliance seeking clear guidelines for prosecuting counterfeit drug offences. In March 2025, the Delhi High Court ruled in favour of Johnson & Johnson, imposing a ₹3.34 crore penalty on Medserve for selling counterfeit medical devices, emphasising the serious threat to public health.


ANTF and DCA Telangana have led multiple successful raids, seizing counterfeit, expired, and unlicensed drugs and arresting key offenders. These actions, supported by the Pharma Task Force and State Drug Officers, disrupted major fake medicine networks. Tackling counterfeit drugs is a critical public health issue, demanding stronger forensic tools, digital traceability, and coordinated national action to safeguard lives and the pharma industry’s integrity.


(Dr. Kumar is a former IPS officer and forensic consultant to Assam government. Das is a student of FSU, Guwahati. Views personal.)

Comments

bottom of page